Navigation Links
Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Date:8/27/2008

SEATTLE, Aug. 27 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that executives will present a corporate update at the upcoming Morgan Stanley Global Healthcare Unplugged Conference to be held at the Grand Hyatt New York on Sept. 9, 2008. Dr. Peter Thompson, president, chief executive officer and chairman, and Dr. Scott C. Stromatt, newly appointed senior vice president and chief medical officer, are scheduled to present on Tuesday, Sept. 9 at 4:30 p.m. EDT. The presentation will be available via audio webcast on Trubion's investor website at investors.trubion.com.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

For more information, contact:

Trubion Pharmaceuticals Inc.

Jim DeNike

Senior Director, Corporate Communications

(206) 838-0500

jdenike@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

(617) 576-5788

amyp@waggeneredstrom.com

TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
5. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
6. Trubion Announces Presentations at April/May Investor Conferences
7. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... NY (PRWEB) , ... January 13, 2017 , ... ... meet every cuvette-related demand that it has found among its diverse customer base. ... for use in most brands electroporators including BTX and Bio-Rad. FireflySci is ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome of ... device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... with short response times capable of performing routine electrochemical biosensing has increased ... electrodes provide fast, sensitive detection and quantification of various analytes in complex ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months to live. ... drug combination that has stabilized Rosendahl’s disease and increased both the quantity and ...
Breaking Biology Technology:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... India , December 7, 2016 According to a ... Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, ... is estimated to grow from USD 6.72 Billion in 2016 to USD 36.07 ... Continue Reading ... ...
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
Breaking Biology News(10 mins):